Medicilon IncMedicilon IncMedicilon IncMedicilon Inc
  • Home
  • About
    • Medicilon Overview
    • Executive Team
    • CEO Message
    • Corporate Culture
    • Company History
    • Honor
  • Services
    • Integrated Projects
      • Antibody-Drug-Antibody (ADC)
      • Preclinical Research Services
      • IND Filing
      • Bio Drug Development
      • Chemical Drug Development
      • Chemical Compound Druggability Assessment
      • Molecular Imaging & Radiochemistry
      • OINDP Development
      • Preclinical Ophthalmic Research Platform
    • Pharmacology Services
      • Cancer Xenograft Models
      • Orthotopic Models
      • Syngeneic Mouse Models
      • Transgenic Mouse Model
      • Humanized Mouse Model (hPBMCEngrafted)
      • PDX Model
      • Digestive System Models
      • Neurological Disorders Models
      • Metabolic Disease Models
      • Inflammation & Immunological Disease Models
      • Other Disease Models
    • Chemistry Services
      • Medicinal Chemistry Services
      • Synthetic Chemistry
      • Process Development Services
      • Analytical Chemistry
    • Drug Formulation
      • Pre Formulation Development
      • Analytical Development
      • Formulation Development Services
      • Generics Consistency Evaluation
      • Research on Quality Control
      • Clinical Trial Material
      • OINDP Development
    • Biology Services
      • Discovery Biology Services
      • Recombinant Protein Services
      • Computational Biology & Molecular Modeling
      • Crystallization & Structural Determination
      • Kinase Services
      • SeMet Media Sales
    • Bioanalytical Services
      • Large Molecule Bioanalysis
      • Small Molecule Bioanalysis
    • Pharmacokinetic Services
      • In Vivo Assays
      • In Vitro Assays
    • Drug Safety Evaluation
      • Inhalation Toxicity Assessment
  • Customer
    • Customer Reviews
    • New Models of Collaboration
    • Intellectual Property Protection
    • Download Center
  • Careers
  • News
    • Medicilon Events
    • Media Coverage
    • Featured Stories
  • Contact

Medicilon – Extraordinary “2 0 1 9”

Home Medicilon Events
NextPrevious

Medicilon – Extraordinary “2 0 1 9”

By medicilon | Medicilon Events | 10 February, 2020 |

In 2019, Medicilon has had an extraordinary year. The steadily developing Medicilon made a huge accumulation in 2019 and achieved a qualitative leap.  Let us look back on the moments of glory and Extraordinary “2 0 1 9”.

2 – Double Happiness

I Listed on Sci-Tech Innovation Board in Shanghai
On Nov. 5th 2019, Shanghai Medicilon Inc. (Medicilon) announced an IPO on Sci-Tech Innovation Board at Shanghai Stock Market, abbreviated as “美迪西”, coded as “688202”.

Speech by Dr. Chunlin Chen, Founder & CEO of Medicilon, during the Listing Ceremony

II 15th Anniversary Events
In 2019, Medicilon held a series of 15th anniversary seminars in different cities of China and United States such as Shanghai and Boston, which attracted more than 2,000 attendees from the pharmaceutical industry to attend.

0 – Medicilon passed GLP and AAALAC reviews with ZERO problem

In January 2019, the NMPA conducted regular inspections of Medicilon’s implementation of GLP. The inspection results showed that the organization and management of pharmaceutical safety evaluation, personnel, equipment and experimental materials, standard operating procedures and trial of Medicilon operations met the GLP requirements and standard.

On November 1, 2019, the AAALAC formally wrote to Medicilon that Medicilon was fully certified by the AAALAC. Since the first passing of the certification in 2009, Medicilon has passed three consecutive certification reviews.

1 – One-stop service CRO helps to obtain clinical approval for 10 IND projects

In 2019, Medicilon helped several pharmaceutical companies to successfully declare 10 new drugs for IND and obtained clinical approval. Of the 10 new drugs, 7 are chemical drugs and 3 are biological drugs.  The customized one-stop R&D services from Medicilon help clients to speed up the new drug development with high quality and standard.

9 – Nine Research Areas

I Drug Discovery – Synthetic Chemistry
Our Lab of Chemistry Department expanded to Nanhui Park in 2019.

II Drug Discovery – Innovative Drug Molecular Design
We have rich experience and technical support in molecular design of innovative drugs. We also have a large FTE team to complete the customized design services for our clients.

III Drug Discovery – Drug Screening
Structural Biology Department has completed several drug screening projects in 2019.

IV Pharmaceutical Research – API
We have completed the construction of the GMP system and the production of 6 GMP projects in 2019.

V Pharmaceutical Research – Preparations
The formulation department has helped 4 projects to successfully obtained approval for consistency evaluation in 2019.

VI Preclinical Studies – Pharmacodynamics
The Pharmacodynamics Department has established more than 200 tumor models and nearly 100 non-tumor target new drug research and evaluation animal models.

VII Preclinical Studies – Pharmacokinetics
The DMPK Department helped the clients to complete several ADC, peptide and other biological macromolecule analysis projects. We also comprehensively provided clinical analysis services.

VIII Preclinical Studies – Drug Safety
In 2019, we established and improved the integrated safety assessment technology platform for ophthalmic drugs and inhaled drugs. We also successfully launched carcinogenic toxicity and stage III reproductive toxicity simulation tests. The data of the tests could support clinical trials at different stages.

IX Preclinical Application of IND New Drug
According to the needs of clients, we can provide one-stop preclinical research services, which comply with both China and International IND standards and requirement.

2019 Medicilon Glory Archive

1. China Business Network awarded Medicilon the Most Growing Enterprise “China Innovation Award”.
2. Medicilon was evaluated as an excellent academician expert workstation.
3. Zhangjiang Group awarded Medicilon the Annual Influential Science and Technology Innovation Enterprise.
4. Shanghai Customs Innovation Demonstration Point, which could enjoy Free Trade Zone Treatment.
5. The Department of Pharmacokinetics and Biological Analysis Passed Proficiency Test by Chinese Academy of Inspection and Quarantine.
6. The Clinic Pathology Office was awarded the Interim Quality Evaluation Certificate of Shanghai Centre for Clinical Laboratory.
7. Re-examined Through Specialization; R&D Institutions in Key New Areas.
8. Zhangjiang Hi-Tech Park awarded Medicilon the “2019 Listed Outstanding Enterprise Award”.

Conclusion

At the height of 2019, we look forward to the future. In 2020, Medicilon will embark on a new journey and sail to a new distance.  The second phase of Nanhui Park was officially launched.  Medicilon was fully preparing to apply for OECD GLP and Reagent Library Platform of Chemistry Department was established.  In 2020, Medicilon is destined to be a more exciting year.  We will continue to maintain our original intention which are pursue excellence, continue to innovate and adhere to the front line of new drug development!

Contact Us:
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500

Drug Discovery, IND, IPO
NextPrevious

News

  • Medicilon Events
  • Media Coverage
  • Featured Stories

Tags

ADME (11) Analytical Method Development (2) animal model (3) Animal Models (46) API (3) API process (3) BIAcore 8K (3) bioanalytical testing (3) Clinical Trails (2) consistency evaluation (3) COVID-19 (3) CRO (13) CRO company (8) CRO industry (6) diabetes treatment (3) Drug Discovery (7) drug safety cro (2) Drug Safety Evaluation (3) Elisa Assay (4) Formulation Research (3) GLP (3) green chemistry (3) IND (2) IND Application (3) IND Filing (5) IPO (3) LC-MS (4) Ligand Binding Assay (4) Medicilon Inc. (2) neurological disease (4) neurological diseases (4) neurological disorder (5) neurological disorders (4) PDX model (3) Peptide Drugs (3) Pharmacokinetics (7) pharmacokinetics research (6) Preclinical Research (6) PROTAC (4) Protein expression (4) Protein Purification (8) SAPA (5) Synthetic Biology (4) T cell (3) Western Blot Analysis (2)

Top Posts

  • 14 August, 2017

    Factors Affecting Pharmacokinetics of Drugs

  • 14 October, 2016

    Preclinical Drug Development Process

  • 14 February, 2017

    IND Enabling Studies FDA

Share

About Us

  • Medicilon Overview
  • Executive Team
  • CEO Message
  • Company History
  • Corporate Culture
  • Honor

Services

  • Chemistry
  • Biology
  • Bioanalytical
  • Drug Safety Evaluation
  • Formulation Development
  • Pharmacology
  • Pharmacokinetic
  • Integrated Projects

Customer Center

  • Customer Reviews
  • Download Center
  • Intellectual Property Protection
  • New Models of Collaboration

Contact Us

Shanghai Medicilon Inc.

Address: No. 585, Chuanda Road, Pudong, Shanghai, 201200, China
Email: Marketing@medicilon.com
Website: www.medicilon.com

Copyright 2017 Shanghai Medicilon inc. | All Rights Reserved Privacy Policy
  • Languages
  • 中国日本대한민국
  • Home
  • About
    • Medicilon Overview
    • Executive Team
    • CEO Message
    • Corporate Culture
    • Company History
    • Honor
  • Services
    • Integrated Projects
      • Antibody-Drug-Antibody (ADC)
      • Preclinical Research Services
      • IND Filing
      • Bio Drug Development
      • Chemical Drug Development
      • Chemical Compound Druggability Assessment
      • Molecular Imaging & Radiochemistry
      • OINDP Development
      • Preclinical Ophthalmic Research Platform
    • Pharmacology Services
      • Cancer Xenograft Models
      • Orthotopic Models
      • Syngeneic Mouse Models
      • Transgenic Mouse Model
      • Humanized Mouse Model (hPBMCEngrafted)
      • PDX Model
      • Digestive System Models
      • Neurological Disorders Models
      • Metabolic Disease Models
      • Inflammation & Immunological Disease Models
      • Other Disease Models
    • Chemistry Services
      • Medicinal Chemistry Services
      • Synthetic Chemistry
      • Process Development Services
      • Analytical Chemistry
    • Drug Formulation
      • Pre Formulation Development
      • Analytical Development
      • Formulation Development Services
      • Generics Consistency Evaluation
      • Research on Quality Control
      • Clinical Trial Material
      • OINDP Development
    • Biology Services
      • Discovery Biology Services
      • Recombinant Protein Services
      • Computational Biology & Molecular Modeling
      • Crystallization & Structural Determination
      • Kinase Services
      • SeMet Media Sales
    • Bioanalytical Services
      • Large Molecule Bioanalysis
      • Small Molecule Bioanalysis
    • Pharmacokinetic Services
      • In Vivo Assays
      • In Vitro Assays
    • Drug Safety Evaluation
      • Inhalation Toxicity Assessment
  • Customer
    • Customer Reviews
    • New Models of Collaboration
    • Intellectual Property Protection
    • Download Center
  • Careers
  • News
    • Medicilon Events
    • Media Coverage
    • Featured Stories
  • Contact
Medicilon Inc